Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
Primary Purpose
Dravet Syndrome
Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Cannabidiol Oral Solution
Placebo Solution
Sponsored by
About this trial
This is an interventional treatment trial for Dravet Syndrome focused on measuring Treatment-resistant seizures
Eligibility Criteria
Inclusion Criteria:
- Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory DS and onset of seizures according to protocol-specified criteria
- Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
- In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet
Exclusion Criteria:
- Medical history is outside protocol-specified parameters
- Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
- Inadequate supervision by parents or guardians
- History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
- Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Cannabidiol Oral Solution
Placebo Solution
Arm Description
Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
Outcomes
Primary Outcome Measures
Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
Secondary Outcome Measures
Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
Percent change from baseline in the frequency of all seizure activity independent of seizure type
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)
Change from baseline in Investigator CGI-I
Change from baseline in Investigator CGI-S
Full Information
NCT ID
NCT02318563
First Posted
December 12, 2014
Last Updated
January 2, 2018
Sponsor
INSYS Therapeutics Inc
1. Study Identification
Unique Protocol Identification Number
NCT02318563
Brief Title
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
Official Title
A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor elected not to continue with study.
Study Start Date
December 30, 2017 (Anticipated)
Primary Completion Date
June 17, 2018 (Anticipated)
Study Completion Date
June 17, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
INSYS Therapeutics Inc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This Phase 3 study will enroll participants diagnosed with Dravet Syndrome (DS) who are still experiencing at least one tonic-clonic, clonic, and/or focal seizures with motor components (FSMC) per week, despite ongoing treatment with up to three antiepileptic drugs (AEDs), and meet the other inclusion/exclusion criteria.
Following a 28-day baseline period, participants will begin an 84-day treatment period. Participants will be assigned to receive twice-daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial.
Following study completion, all participants will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dravet Syndrome
Keywords
Treatment-resistant seizures
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cannabidiol Oral Solution
Arm Type
Experimental
Arm Description
Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
Arm Title
Placebo Solution
Arm Type
Placebo Comparator
Arm Description
Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
Intervention Type
Drug
Intervention Name(s)
Cannabidiol Oral Solution
Intervention Description
An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
Intervention Type
Drug
Intervention Name(s)
Placebo Solution
Intervention Description
A matching oral solution containing no cannabidiol
Primary Outcome Measure Information:
Title
Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Secondary Outcome Measure Information:
Title
Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Percent change from baseline in the frequency of all seizure activity independent of seizure type
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Change from baseline in Investigator CGI-I
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
Title
Change from baseline in Investigator CGI-S
Time Frame
Data point for observation period to data point for treatment period Weeks 9 through 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory DS and onset of seizures according to protocol-specified criteria
Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet
Exclusion Criteria:
Medical history is outside protocol-specified parameters
Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
Inadequate supervision by parents or guardians
History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neha Parikh
Organizational Affiliation
INSYS Therapeutics Inc
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
We'll reach out to this number within 24 hrs